Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹209.45
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹262.08B
Enterprise Value₹223.95K
Total Cash (Recent Filing)₹13.55B
Total Debt (Recent Filing)₹56.75B
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend Yield0.07%
Share Statistics
EPS (TTM)-2.47
Shares Outstanding1,331,348,100
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.45
Revenue Forecast (FY)₹100.54B
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (CDMO, Hospital Generics, OTC)Piramal Pharma’s presence across CDMO, complex hospital/generics and consumer healthcare creates multiple durable revenue streams. CDMO provides long-term contract revenue; hospital/specialty drugs add differentiated product economics; OTC offers stable retail cashflows and distribution leverage.
Strong Multi-year Revenue ScalingSustained top-line growth over several years indicates expanding market share and successful commercialization across segments. Larger revenue scale supports fixed-cost absorption, capacity utilization and negotiating power with customers, improving structural operating leverage potential.
Improved Cash Generation And Positive FCF In FY2026Material improvement in operating cash flow and a return to positive free cash flow enhances financial flexibility. Positive FCF provides durable funding for capex, debt repayment or reinvestment in CDMO capabilities, reducing reliance on external financing if sustained.
Bears Say
Profitability Volatility And Recurring Net LossesRepeated swings into net losses demonstrate fragile earnings quality and make long-term forecasting difficult. Volatile profitability limits retained earnings, constrains reinvestment and raises the risk that scale does not translate into consistent shareholder returns unless structural cost or revenue issues are resolved.
Rising Debt Burden Relative To EquityMaterial increase in debt elevates financial risk, especially with uneven profitability. Higher leverage raises interest and refinancing pressure, narrows strategic flexibility for M&A or capex, and exacerbates downside if earnings and cash generation weaken again.
Historical Free Cash Flow InstabilityAlthough FCF became positive in FY2026, prior years of negative free cash flow indicate inconsistent conversion of revenue into durable cash. This history implies the recent improvement may be cyclical; sustainability must be demonstrated across multiple periods to de-risk funding and investment plans.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹209.45 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹262.08B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Nov 11, 2026 which is in 101 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Jul 29, 2026. The company reported -₹0.5 earnings per share for the quarter, beating the consensus estimate of -₹0.66 by ₹0.16.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.07%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.01.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,331,348,100 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of -₹0.5 in its last earnings report, beating expectations of -₹0.66. Following the earnings report the stock price went up 1.215%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―